Press releases

Volastra Therapeutics Appoints David Nicholson, Ph.D., to Board of Directors

Volastra Therapeutics, a clinical-stage cancer biotechnology company, has appointed David Nicholson, Ph.D., as an independent member of its Board of Directors.

Volastra Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of VLS-1488, One in a Portfolio of Novel and Differentiated KIF18A Inhibitors

Volastra Therapeutics, a discovery and clinical-stage cancer biotechnology company, today announced the dosing of the first patient in a Phase I/II clinical trial evaluating VLS-1488.

Preclinical Data on Volastra Therapeutics’ Two Novel and Differentiated KIF18A Inhibitors Presented at AACR 2023

NEW YORK, April 16, 2023 – Volastra Therapeutics, a clinical-stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), today […]

Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline

Financing led by founding investors Polaris Partners and ARCH Venture Partners alongside Lilly.  Funding will support clinical development of Volastra’s […]

Volastra Therapeutics Appoints David Nicholson, Ph.D., to Board of Directors

Volastra Therapeutics, a clinical-stage cancer biotechnology company, has appointed David Nicholson, Ph.D., as an independent member of its Board of Directors.

Volastra Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of VLS-1488, One in a Portfolio of Novel and Differentiated KIF18A Inhibitors

Volastra Therapeutics, a discovery and clinical-stage cancer biotechnology company, today announced the dosing of the first patient in a Phase I/II clinical trial evaluating VLS-1488.

Preclinical Data on Volastra Therapeutics’ Two Novel and Differentiated KIF18A Inhibitors Presented at AACR 2023

NEW YORK, April 16, 2023 – Volastra Therapeutics, a clinical-stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), today […]

Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline

Financing led by founding investors Polaris Partners and ARCH Venture Partners alongside Lilly.  Funding will support clinical development of Volastra’s […]

A closer look at Volastra’s lead program: KIF18A inhibitor

By Christina Eng, Ph.D., VP, Head of Biology Earlier this month at the FASEB Consequences of Aneuploidy conference, we shared […]

Volastra Therapeutics Named One of Fierce Biotech’s “Fierce 15” Companies of 2022

NEW YORK, September 12, 2022 – Volastra Therapeutics, an oncology company focused on exploiting chromosomal instability to treat cancer, today […]